$261 Million is the total value of Avoro Capital Advisors LLC's 33 reported holdings in Q1 2015. The portfolio turnover from Q4 2014 to Q1 2015 was 90.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Buy | AMICUS THERAPEUTICS INC | $45,820,000 | +95.0% | 4,211,399 | +49.1% | 17.58% | +10.5% |
| LBIO | New | LION BIOTECHNOLOGIES INC | $26,035,000 | – | 2,149,907 | +100.0% | 9.99% | – |
| SRNE | Buy | SORRENTO THERAPEUTICS INC | $25,594,000 | +179.3% | 2,214,043 | +143.3% | 9.82% | +58.2% |
| New | CELGENE CORP. | $17,154,000 | – | 148,800 | +100.0% | 6.58% | – | |
| PTX | Buy | PERNIX THERAPEUTICS HOLDINGS | $14,914,000 | +40.0% | 1,395,167 | +23.0% | 5.72% | -20.7% |
| BLCM | Buy | BELLICUM PHARMACEUTICALS INC | $11,006,000 | +117.1% | 475,015 | +115.9% | 4.22% | +23.0% |
| AGEN | Sell | AGENUS - INC | $10,506,000 | +0.3% | 2,047,971 | -22.4% | 4.03% | -43.2% |
| EBS | EMERGENT BIOSOLUTIONS INC | $9,509,000 | +5.6% | 330,635 | 0.0% | 3.65% | -40.2% | |
| MRTX | New | MIRATI THERAPEUTICS INC. | $9,408,000 | – | 320,867 | +100.0% | 3.61% | – |
| LJPC | Buy | LA JOLLA PHARMACEUTICAL CO. | $8,445,000 | +85.7% | 461,499 | +87.2% | 3.24% | +5.2% |
| TARO | Sell | TARO PHARMACEUTICAL INDUSshares | $7,587,000 | -38.9% | 53,800 | -35.8% | 2.91% | -65.4% |
| ONTY | Buy | ONCOTHYREON INC | $7,321,000 | +28.8% | 4,491,636 | +50.1% | 2.81% | -27.0% |
| RCPT | Sell | RECEPTOS INC | $7,255,000 | -32.3% | 44,000 | -49.7% | 2.78% | -61.7% |
| STML | New | STEMLINE THERAPEUTICS - INC | $6,873,000 | – | 475,000 | +100.0% | 2.64% | – |
| IG | Buy | IGI LABORATORIES INC | $5,883,000 | +44.6% | 720,908 | +55.9% | 2.26% | -18.1% |
| QURE | New | UNIQURE N V | $5,507,000 | – | 226,456 | +100.0% | 2.11% | – |
| TNXP | New | TONIX PHARMACEUTICALS HLDG | $4,773,000 | – | 755,300 | +100.0% | 1.83% | – |
| VCEL | VERICEL CORP. | $3,918,000 | +21.7% | 1,058,820 | 0.0% | 1.50% | -31.0% | |
| FLML | Buy | FLAMEL TECHNOLOGIESsponsored adr | $3,878,000 | +5.4% | 215,705 | +0.4% | 1.49% | -40.3% |
| SGMO | New | SANGAMO BIOSCIENCES INC | $3,829,000 | – | 244,199 | +100.0% | 1.47% | – |
| New | TRILLIUM THERAPEUTICS INC | $3,234,000 | – | 160,697 | +100.0% | 1.24% | – | |
| EXELIXIS INC EXEL 20190815 4.250000%notes | $3,234,000 | +34.9% | 4,250,000 | 0.0% | 1.24% | -23.6% | ||
| CCXI | New | CHEMOCENTRYX - INC | $2,443,000 | – | 323,607 | +100.0% | 0.94% | – |
| TXMD | New | THERAPEUTICS MD INC | $2,372,000 | – | 392,000 | +100.0% | 0.91% | – |
| CNDO | New | CORONADO BIOSCIENCES INC | $2,310,000 | – | 600,000 | +100.0% | 0.89% | – |
| TROV | New | TROVAGENE INC | $2,205,000 | – | 323,728 | +100.0% | 0.85% | – |
| RXDX | Sell | IGNYTA INC. | $1,998,000 | -44.0% | 200,772 | -61.5% | 0.77% | -68.3% |
| INNL | INNOCOLL AGsponsored adr | $1,689,000 | +26.5% | 225,000 | 0.0% | 0.65% | -28.3% | |
| HTBX | New | HEAT BIOLOGICS INC | $1,654,000 | – | 260,000 | +100.0% | 0.64% | – |
| BIOL | Sell | BIOLASE INC | $1,394,000 | -32.4% | 690,000 | -12.0% | 0.54% | -61.7% |
| TRGT | New | TARGACEPT INC | $1,385,000 | – | 466,297 | +100.0% | 0.53% | – |
| CLLS | New | CELLECTISsponsored ads | $1,037,000 | – | 30,000 | +100.0% | 0.40% | – |
| ALIM | Sell | ALIMERA SCIENCES INC | $408,000 | -88.0% | 81,372 | -87.9% | 0.16% | -93.2% |
| EXAS | Exit | EXACT SCIENCES CORP.put | $0 | – | -9,600 | -100.0% | -0.00% | – |
| CBSTZ | Exit | CUBIST PHARMA-RTSrights | $0 | – | -141,688 | -100.0% | -0.00% | – |
| RCPT | Exit | RECEPTOS INCput | $0 | – | -20,000 | -100.0% | -0.06% | – |
| BOTA | Exit | BIOTA PHARMACEUTICALS- INC | $0 | – | -258,586 | -100.0% | -0.39% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -65,900 | -100.0% | -0.45% | – |
| FWP | Exit | FORWARD PHARMA A/S-ADRsponsored adr | $0 | – | -50,000 | -100.0% | -0.71% | – |
| CPRX | Exit | CATALYST PHARMACEUTICAL PART.. | $0 | – | -550,670 | -100.0% | -1.11% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -300,000 | -100.0% | -1.20% | – |
| DVAX | Exit | DYNAVAX TECHNOLOGIES CORP | $0 | – | -199,332 | -100.0% | -2.28% | – |
| ARWR | Exit | ARROWHEAD RESEARCH - CORP | $0 | – | -525,000 | -100.0% | -2.62% | – |
| CELG | Exit | CELGENE CORP.call | $0 | – | -150,000 | -100.0% | -2.66% | – |
| Exit | MACROGENICS INC. | $0 | – | -162,500 | -100.0% | -3.86% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.